Figure 3.
Anti-CD200 antibody effectively targets MCC tumor cells in vivo. (A) schematic of experiment illustrating the intravenous infusion of human IgG4 anti-CD200 antibody followed by 6-hour washout period. The MCC xenograft tumor was then collected and tissues were stained with an anti-human-IgG secondary antibody. (B) Anti-CD200 antibody was not detected in overlying mouse epidermis, (C) but heavily deposited on viable MCC tumor cells.